SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 21,528 Shares

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 21,528 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $15.37, for a total value of $330,885.36. Following the completion of the sale, the chief financial officer owned 266,466 shares of the company’s stock, valued at $4,095,582.42. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, January 2nd, Anshul Maheshwari sold 5,229 shares of SiBone stock. The shares were sold at an average price of $19.64, for a total value of $102,697.56.
• On Thursday, December 18th, Anshul Maheshwari sold 18,542 shares of SiBone stock. The stock was sold at an average price of $20.15, for a total value of $373,621.30.
• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total value of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The shares were sold at an average price of $20.01, for a total value of $24,012.00.

SiBone Trading Up 3.2%

SiBone stock opened at $15.74 on Thursday. SiBone has a 12-month low of $12.49 and a 12-month high of $21.89. The firm has a market capitalization of $682.96 million, a price-to-earnings ratio of -30.86 and a beta of 0.69. The firm has a 50 day moving average of $17.97 and a 200 day moving average of $16.86. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SIBN. Morgan Stanley increased their price target on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Canaccord Genuity Group lifted their target price on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Truist Financial boosted their price target on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Needham & Company LLC increased their price objective on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

Institutional Investors Weigh In On SiBone

Several large investors have recently added to or reduced their stakes in the stock. Susquehanna Portfolio Strategies LLC lifted its stake in shares of SiBone by 579.2% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 105,365 shares of the company’s stock worth $2,078,000 after acquiring an additional 89,851 shares during the last quarter. Tudor Investment Corp ET AL lifted its position in shares of SiBone by 0.6% during the fourth quarter. Tudor Investment Corp ET AL now owns 259,589 shares of the company’s stock worth $5,119,000 after purchasing an additional 1,557 shares during the last quarter. Man Group plc purchased a new stake in shares of SiBone during the fourth quarter valued at $965,000. Inspire Investing LLC purchased a new stake in shares of SiBone during the fourth quarter valued at $1,246,000. Finally, Cinctive Capital Management LP bought a new position in shares of SiBone in the fourth quarter worth about $878,000. 98.11% of the stock is owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.